Exagen_Full_CMYK_Print.jpg
Exagen to Announce Second Quarter Financial Results on July 28, 2020
July 16, 2020 10:45 ET | Exagen Inc.
SAN DIEGO, July 16, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Exagen_Full_CMYK_Print.jpg
Exagen and the Ohio State Innovation Foundation Announce Exclusive License Agreement and Research Collaboration for a Novel, Rule-In, Blood Test to Support the Diagnosis of Fibromyalgia
June 17, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
1589314014021_5ebaf5bc8fd6a60004fbd876_logo.png
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA)
June 15, 2020 08:00 ET | Navidea Biopharmaceuticals, Inc.
DUBLIN, OH, June 15, 2020 (GLOBE NEWSWIRE) -- Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Announces Clinical Trial Conducted at Major Academic Center in Distinguishing Type 1 and Type 2 Lupus
June 03, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, June 03, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, announced today...
Exagen_Full_CMYK_Print.jpg
Exagen to Present at the William Blair 40th Annual Growth Stock Conference
May 26, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, May 26, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today announced...
Exagen_Full_CMYK_Print.jpg
Exagen Inc. Reports First Quarter 2020 Results
May 11, 2020 16:05 ET | Exagen Inc.
SAN DIEGO, May 11, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, today reported...
setpoint_facebook.jpg
SetPoint Medical Receives IDE Approval for U.S. Pivotal Trial to Study its Bioelectronic Platform in Rheumatoid Arthritis Patients
May 06, 2020 09:00 ET | SetPoint Medical
VALENCIA, Calif., May 06, 2020 (GLOBE NEWSWIRE) -- SetPoint Medical, a clinical-stage bioelectronic medicine company developing therapy for chronic autoimmune diseases, today announced that it has...
Exagen_Full_CMYK_Print.jpg
Exagen to Announce First Quarter Financial Results on May 11, 2020
April 27, 2020 08:25 ET | Exagen Inc.
SAN DIEGO, April 27, 2020 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), an organization dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune...
fior-markets-logo.jpg
Global Hydroxychloroquine Market Is Expected to Reach 5,549.65 Million by 2027 : Fior Markets
April 10, 2020 05:12 ET | Fior Markets
Newark, NJ, April 10, 2020 (GLOBE NEWSWIRE) -- As per the report published by Fior Markets, the global hydroxychloroquine market is expected to grow from USD 542.36 million in 2019 and to reach USD...
logo long.jpg
Global Hydroxychloroquine Market to Surpass US$ 6,781.1 Million by 2027, Corona virus (COVID-19) outbreak to propel Market growth
April 07, 2020 10:18 ET | CMI
SEATTLE, April 07, 2020 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, the global hydroxychloroquine market is estimated to be valued at US$ 484.9 million in 2019 and is expected to...